Gene therapy for children and adults with diffuse midline glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a modified herpes virus (M032) given directly into the brain tumor after standard radiation. The goal is to see if this virus can slow or stop the growth of diffuse midline glioma, a type of brain cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be at least 3 years old.
- Must have a newly diagnosed diffuse midline glioma (a brain tumor), with a specific genetic change called H3 K27M, confirmed by biopsy or MRI.
- You must have finished standard radiation therapy between 4 and 8 weeks before starting the study.
- The tumor must be between 1 and 4 centimeters in size and reachable by surgery.
- You must be healthy enough for surgery and have normal blood counts and organ function.
- If you could become pregnant, you must agree to use effective birth control during the study and for a time after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a “suicide gene” therapy delivered by a virus along with radiation for adults whose high-grade brain tumor has come back or grown again. The goal is to see if the treatment is safe and can help control the tumor.
This trial tests whether a special herpes virus (G207) combined with low-dose radiation can help children with high-grade brain tumors (gliomas). The virus is injected into the tumor to attack the cancer cells while radiation helps boost the effect.
This trial studies a gene-based treatment (HSV-tk) given with radiation and chemotherapy for people newly diagnosed with glioblastoma or anaplastic astrocytoma. It may help the new brain tumor respond better to standard treatments, though risks and benefits are still being tested.
This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.